Genocea Biosciences Stock Price, News & Analysis (NASDAQ:GNCA)

$1.00 +0.02 (+2.04 %)
(As of 02/19/2018 04:00 PM ET)
Previous Close$1.00
Today's Range$0.96 - $1.01
52-Week Range$0.79 - $7.29
Volume314,950 shs
Average Volume1.23 million shs
Market Capitalization$82.07 million
P/E Ratio-0.51
Dividend YieldN/A
Beta1.55

About Genocea Biosciences (NASDAQ:GNCA)

Genocea Biosciences logoGenocea Biosciences, Inc., is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company has one product candidate in Phase III clinical development, GEN-003, an immunotherapy for the treatment of genital herpes. It also has a pre-clinical immuno-oncology program focused on personalized cancer vaccines (GEN-009). The GEN-009 program leverages ATLAS to identify patient neoantigens, or newly formed antigens unique to each patient, that are associated with that individual's tumor.

Receive GNCA News and Ratings via Email

Sign-up to receive the latest news and ratings for GNCA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:GNCA
CUSIPN/A
Phone+1-617-8768191

Debt

Debt-to-Equity Ratio2.51%
Current Ratio1.55%
Quick Ratio1.55%

Price-To-Earnings

Trailing P/E Ratio-0.505050505050505
Forward P/E Ratio-1.30
P/E GrowthN/A

Sales & Book Value

Annual Sales$230,000.00
Price / Sales356.83
Cash FlowN/A
Price / CashN/A
Book Value$1.60 per share
Price / Book0.63

Profitability

Trailing EPS($1.98)
Net Income$-56,710,000.00
Net MarginsN/A
Return on Equity-304.02%
Return on Assets-134.71%

Miscellaneous

Employees98
Outstanding Shares82,070,000

Genocea Biosciences (NASDAQ:GNCA) Frequently Asked Questions

What is Genocea Biosciences' stock symbol?

Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."

How were Genocea Biosciences' earnings last quarter?

Genocea Biosciences Inc (NASDAQ:GNCA) issued its quarterly earnings data on Friday, February, 16th. The biotechnology company reported ($0.37) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.40) by $0.03. View Genocea Biosciences' Earnings History.

When will Genocea Biosciences make its next earnings announcement?

Genocea Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Genocea Biosciences.

Where is Genocea Biosciences' stock going? Where will Genocea Biosciences' stock price be in 2018?

5 Wall Street analysts have issued 12-month price targets for Genocea Biosciences' stock. Their forecasts range from $2.50 to $10.00. On average, they anticipate Genocea Biosciences' share price to reach $4.70 in the next twelve months. View Analyst Ratings for Genocea Biosciences.

Are investors shorting Genocea Biosciences?

Genocea Biosciences saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 2,870,612 shares, an increase of 73.9% from the January 12th total of 1,651,170 shares. Based on an average daily trading volume, of 1,916,972 shares, the short-interest ratio is presently 1.5 days. Currently, 6.7% of the shares of the company are short sold.

Who are some of Genocea Biosciences' key competitors?

Who are Genocea Biosciences' key executives?

Genocea Biosciences' management team includes the folowing people:

  • Katrine S. Bosley, Chairman of the Board (Age 49)
  • William D. Clark, President, Chief Executive Officer, Director (Age 55)
  • Jonathan M. Poole, Chief Financial Officer (Age 42)
  • John E. Bishop Ph.D., Executive Vice President - Pharmaceutical Sciences (Age 54)
  • Jessica Baker Flechtner Ph.D., Chief Scientific Officer (Age 44)
  • Eric S. Hoffman Ph.D., Chief Business Officer (Age 47)
  • Ali Behbahani M.D., Director (Age 41)
  • Ronald Harold Wilfred Cooper, Director (Age 54)
  • George R Siber, Director
  • Kenneth M. Bate, Independent Director (Age 66)

Who owns Genocea Biosciences stock?

Genocea Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (0.15%). Company insiders that own Genocea Biosciences stock include Eric S Hoffman, Jonathan Poole and William D Clark. View Institutional Ownership Trends for Genocea Biosciences.

Who bought Genocea Biosciences stock? Who is buying Genocea Biosciences stock?

Genocea Biosciences' stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC. Company insiders that have bought Genocea Biosciences stock in the last two years include Eric S Hoffman, Jonathan Poole and William D Clark. View Insider Buying and Selling for Genocea Biosciences.

How do I buy Genocea Biosciences stock?

Shares of Genocea Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Genocea Biosciences' stock price today?

One share of Genocea Biosciences stock can currently be purchased for approximately $1.00.

How big of a company is Genocea Biosciences?

Genocea Biosciences has a market capitalization of $82.07 million and generates $230,000.00 in revenue each year. The biotechnology company earns $-56,710,000.00 in net income (profit) each year or ($1.98) on an earnings per share basis. Genocea Biosciences employs 98 workers across the globe.

How can I contact Genocea Biosciences?

Genocea Biosciences' mailing address is 100 Acorn Park Dr, CAMBRIDGE, MA 02140-2303, United States. The biotechnology company can be reached via phone at +1-617-8768191 or via email at [email protected]


MarketBeat Community Rating for Genocea Biosciences (GNCA)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  189 (Vote Outperform)
Underperform Votes:  109 (Vote Underperform)
Total Votes:  298
MarketBeat's community ratings are surveys of what our community members think about Genocea Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Genocea Biosciences (NASDAQ:GNCA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.802.602.603.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.70$7.38$7.38$21.75
Price Target Upside: 405.38% upside535.78% upside535.78% upside273.07% upside

Genocea Biosciences (NASDAQ:GNCA) Consensus Price Target History

Price Target History for Genocea Biosciences (NASDAQ:GNCA)

Genocea Biosciences (NASDAQ:GNCA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/12/2018Robert W. BairdInitiated CoverageOutperform$3.00HighView Rating Details
2/6/2018Needham & Company LLCUpgradeHold -> Buy$3.00HighView Rating Details
11/2/2017Piper Jaffray CompaniesReiterated RatingOverweight$5.00N/AView Rating Details
9/26/2017CowenReiterated RatingBuy$10.00HighView Rating Details
9/25/2017Stifel NicolausDowngradeBuy -> Hold$15.00 -> $2.50HighView Rating Details
1/23/2017FBR & CoReiterated RatingOutperformN/AView Rating Details
(Data available from 2/19/2016 forward)

Earnings

Genocea Biosciences (NASDAQ:GNCA) Earnings History and Estimates Chart

Earnings by Quarter for Genocea Biosciences (NASDAQ:GNCA)

Genocea Biosciences (NASDAQ GNCA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018($0.15)N/AView Earnings Details
2/16/2018Q4 2017($0.40)($0.37)ViewN/AView Earnings Details
11/2/2017Q3 2017($0.51)($0.59)ViewN/AView Earnings Details
8/9/2017Q2 2017($0.46)($0.54)ViewN/AView Earnings Details
5/4/20173/31/2017($0.54)($0.48)ViewListenView Earnings Details
2/16/2017Q416($0.45)($0.56)ViewN/AView Earnings Details
11/3/2016Q316($0.44)($0.45)ViewN/AView Earnings Details
8/4/2016Q216($0.44)($0.39)ViewN/AView Earnings Details
5/5/2016Q116($0.42)($0.35)$0.24 millionViewN/AView Earnings Details
2/11/2016Q415($0.40)($0.37)$0.22 millionViewListenView Earnings Details
11/5/2015Q315($0.43)($0.37)$0.21 millionViewListenView Earnings Details
8/6/2015Q215($0.51)($0.43)$0.12 millionViewN/AView Earnings Details
5/7/2015Q115($0.57)($0.64)$0.12 millionViewListenView Earnings Details
2/12/2015Q414($0.53)($0.66)$0.31 millionViewListenView Earnings Details
11/6/2014Q314($0.43)($0.53)ViewN/AView Earnings Details
8/6/2014Q2($0.42)($0.41)ViewN/AView Earnings Details
5/6/2014Q114($0.60)($0.76)$0.26 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Genocea Biosciences (NASDAQ:GNCA) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.77 EPS
Next Year EPS Consensus Estimate: $-0.81 EPS

Dividends

Dividend History for Genocea Biosciences (NASDAQ:GNCA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Genocea Biosciences (NASDAQ GNCA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.70%
Institutional Ownership Percentage: 10.10%
Insider Trades by Quarter for Genocea Biosciences (NASDAQ:GNCA)
Institutional Ownership by Quarter for Genocea Biosciences (NASDAQ:GNCA)

Genocea Biosciences (NASDAQ GNCA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/17/2018William D ClarkCEOBuy25,000$0.80$20,000.0082,931View SEC Filing  
7/24/2017Jonathan PooleCFOSell45,000$6.00$270,000.0084,247View SEC Filing  
11/8/2016Eric S. HoffmanInsiderBuy7,000$3.49$24,430.00View SEC Filing  
11/7/2016Jonathan PooleCFOBuy7,000$3.34$23,380.00View SEC Filing  
11/7/2016William D. ClarkInsiderBuy2,800$3.49$9,772.00View SEC Filing  
5/9/2016Jonathan PooleCFOBuy4,000$3.88$15,520.008,213View SEC Filing  
12/16/2015William D ClarkCEOBuy3,800$6.45$24,510.0043,607View SEC Filing  
9/1/2015Jessica Baker FlechtnerVPSell2,229$11.35$25,299.151,881View SEC Filing  
6/19/2015Polaris Venture Management Co.Major ShareholderSell30,004$13.04$391,252.16View SEC Filing  
6/17/2015Polaris Venture Management Co.Major ShareholderSell10,618$13.01$138,140.18View SEC Filing  
6/16/2015Polaris Venture Management Co.Major ShareholderSell46,000$13.24$609,040.00View SEC Filing  
6/1/2015Jessica Baker FlechtnerVPSell2,229$10.52$23,449.08View SEC Filing  
5/1/2015Jessica Baker FlechtnerVPSell2,229$10.21$22,758.09View SEC Filing  
4/1/2015Jessica Baker FlechtnerVPSell2,283$11.77$26,870.91View SEC Filing  
3/17/2015Stephen J HoffmanDirectorBuy700,000$8.25$5,775,000.00View SEC Filing  
2/2/2015Jessica Baker FlechtnerVPSell4,699$8.50$39,941.50View SEC Filing  
9/12/2014Jessica Baker FlechtnerVPSell6,435$12.00$77,220.00View SEC Filing  
9/11/2014Paul GiannascaVPSell4,071$11.84$48,200.64View SEC Filing  
9/10/2014Paul GiannascaVPSell834$12.35$10,299.90View SEC Filing  
9/9/2014Paul GiannascaVPSell2,455$12.43$30,515.65View SEC Filing  
9/8/2014Paul GiannascaVPSell2,970$12.80$38,016.00View SEC Filing  
8/29/2014Paul GiannascaVPSell6,760$12.50$84,500.00View SEC Filing  
8/14/2014Polaris Venture Management Co.Major ShareholderSell9,660$13.01$125,676.60View SEC Filing  
8/12/2014Polaris Venture Management Co.Major ShareholderSell63,794$13.28$847,184.32View SEC Filing  
2/10/2014Plc GlaxosmithklineInsiderBuy143,773$12.00$1,725,276.00View SEC Filing  
2/10/2014Polaris Venture Management Co.Major ShareholderBuy232,820$12.00$2,793,840.00View SEC Filing  
2/10/2014Stephen J HoffmanDirectorBuy250,931$12.00$3,011,172.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Genocea Biosciences (NASDAQ GNCA) News Headlines

Source:
DateHeadline
Genocea Biosciences (GNCA) Releases Quarterly  Earnings Results, Beats Expectations By $0.03 EPSGenocea Biosciences (GNCA) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS
www.americanbankingnews.com - February 16 at 11:40 AM
Genocea Biosciences, Inc. to Host Earnings CallGenocea Biosciences, Inc. to Host Earnings Call
finance.yahoo.com - February 15 at 9:29 AM
Genocea Reports Fourth Quarter and Full-Year 2017 Financial ResultsGenocea Reports Fourth Quarter and Full-Year 2017 Financial Results
finance.yahoo.com - February 15 at 9:29 AM
Genocea Biosciences (GNCA) Appoints Ali Behbahani M.D. to BoardGenocea Biosciences (GNCA) Appoints Ali Behbahani M.D. to Board
www.streetinsider.com - February 13 at 9:58 AM
NEA Partner Ali Behbahani, M.D. Joins Genocea Biosciences’ Board of DirectorsNEA Partner Ali Behbahani, M.D. Joins Genocea Biosciences’ Board of Directors
finance.yahoo.com - February 13 at 9:58 AM
Genocea Biosciences (GNCA) Earns Outperform Rating from Analysts at Robert W. BairdGenocea Biosciences (GNCA) Earns Outperform Rating from Analysts at Robert W. Baird
www.americanbankingnews.com - February 12 at 9:00 PM
Short Interest in Genocea Biosciences Inc (GNCA) Grows By 73.9%Short Interest in Genocea Biosciences Inc (GNCA) Grows By 73.9%
www.americanbankingnews.com - February 9 at 4:58 PM
Genocea to Host Fourth Quarter and Year End 2017 Financial Results Conference Call & Webcast on February 15, 2018 at 9 a.m. ETGenocea to Host Fourth Quarter and Year End 2017 Financial Results Conference Call & Webcast on February 15, 2018 at 9 a.m. ET
finance.yahoo.com - February 8 at 8:11 AM
Genocea Biosciences (GNCA) Scheduled to Post Quarterly Earnings on WednesdayGenocea Biosciences (GNCA) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - February 7 at 2:14 AM
Genocea Biosciences (GNCA) Upgraded by Needham & Company LLC to "Buy"Genocea Biosciences (GNCA) Upgraded by Needham & Company LLC to "Buy"
www.americanbankingnews.com - February 6 at 11:30 PM
Genocea Biosciences: 200% Dilution, Hopelessness And Anger ... - Seeking AlphaGenocea Biosciences: 200% Dilution, Hopelessness And Anger ... - Seeking Alpha
seekingalpha.com - February 3 at 9:30 AM
 Analysts Anticipate Genocea Biosciences Inc (GNCA) to Post -$0.38 Earnings Per Share Analysts Anticipate Genocea Biosciences Inc (GNCA) to Post -$0.38 Earnings Per Share
www.americanbankingnews.com - February 3 at 3:12 AM
Genocea Biosciences Inc (GNCA) Receives Consensus Rating of "Hold" from AnalystsGenocea Biosciences Inc (GNCA) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - January 27 at 9:04 AM
Genocea Biosciences Inc (GNCA) CEO William D. Clark Acquires 25,000 SharesGenocea Biosciences Inc (GNCA) CEO William D. Clark Acquires 25,000 Shares
www.americanbankingnews.com - January 19 at 4:46 PM
Genocea Biosciences, Inc. Announces Proposed Concurrent Public ... - GlobeNewswire (press release)Genocea Biosciences, Inc. Announces Proposed Concurrent Public ... - GlobeNewswire (press release)
globenewswire.com - January 18 at 4:55 PM
Genocea Biosciences (GNCA) Prices $55M Concurrent Public Offerings - StreetInsider.comGenocea Biosciences (GNCA) Prices $55M Concurrent Public Offerings - StreetInsider.com
www.streetinsider.com - January 18 at 4:55 PM
Genocea Biosciences (GNCA) Prices $55M Concurrent Public OfferingsGenocea Biosciences (GNCA) Prices $55M Concurrent Public Offerings
www.streetinsider.com - January 17 at 5:30 PM
Genocea Biosciences, Inc. Announces Pricing of $55 Million Concurrent Public OfferingsGenocea Biosciences, Inc. Announces Pricing of $55 Million Concurrent Public Offerings
finance.yahoo.com - January 17 at 9:17 AM
 Brokerages Expect Genocea Biosciences Inc (GNCA) to Announce -$0.38 EPS Brokerages Expect Genocea Biosciences Inc (GNCA) to Announce -$0.38 EPS
www.americanbankingnews.com - January 17 at 5:12 AM
Genocea Biosciences, Inc. Announces Proposed Concurrent Public Offerings of Common Stock and Class A Warrants and Series A Convertible Preferred Stock and Class A WarrantsGenocea Biosciences, Inc. Announces Proposed Concurrent Public Offerings of Common Stock and Class A Warrants and Series A Convertible Preferred Stock and Class A Warrants
finance.yahoo.com - January 16 at 5:18 PM
Critical Review: Genocea Biosciences (GNCA) & The CompetitionCritical Review: Genocea Biosciences (GNCA) & The Competition
www.americanbankingnews.com - January 10 at 8:02 AM
How Do Analysts See Genocea Biosciences Inc (NASDAQ:GNCA) Performing Over The Couple Of Years?How Do Analysts See Genocea Biosciences Inc (NASDAQ:GNCA) Performing Over The Couple Of Years?
finance.yahoo.com - January 3 at 5:24 PM
Glancy Prongay & Murray Reminds Investors of the January 2, 2018 Deadline in the Class Action Lawsuit Against Genocea Biosciences, Inc. (GNCA)Glancy Prongay & Murray Reminds Investors of the January 2, 2018 Deadline in the Class Action Lawsuit Against Genocea Biosciences, Inc. (GNCA)
finance.yahoo.com - January 2 at 6:45 PM
Genocea Biosciences Inc (GNCA) Receives Average Rating of "Hold" from AnalystsGenocea Biosciences Inc (GNCA) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - January 2 at 8:26 AM
Genocea Biosciences (GNCA) & Its Peers Head to Head ComparisonGenocea Biosciences (GNCA) & Its Peers Head to Head Comparison
www.americanbankingnews.com - January 1 at 9:10 PM
Comparing Genocea Biosciences (GNCA) and The CompetitionComparing Genocea Biosciences (GNCA) and The Competition
www.americanbankingnews.com - December 30 at 1:26 AM
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Genocea Bioscience, Inc. (GNCA) & Lead Plaintiff Deadline - January 2, 2018DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Genocea Bioscience, Inc. (GNCA) & Lead Plaintiff Deadline - January 2, 2018
finance.yahoo.com - December 28 at 2:40 PM
Scott+Scott, Attorneys at Law, LLP Reminds Investors that the Lead Plaintiff Deadline in Genocea Biosciences, Inc. (GNCA) Class Action is January 2ndScott+Scott, Attorneys at Law, LLP Reminds Investors that the Lead Plaintiff Deadline in Genocea Biosciences, Inc. (GNCA) Class Action is January 2nd
finance.yahoo.com - December 28 at 2:40 PM
Robbins Arroyo LLP: Genocea Biosciences, Inc. (GNCA) Misled Shareholders According to a Recently Filed Class ActionRobbins Arroyo LLP: Genocea Biosciences, Inc. (GNCA) Misled Shareholders According to a Recently Filed Class Action
finance.yahoo.com - December 28 at 2:40 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Genocea Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadline – GNCASHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Genocea Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadline – GNCA
finance.yahoo.com - December 23 at 7:48 PM
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Genocea Biosciences, Inc. - GNCAEQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Genocea Biosciences, Inc. - GNCA
finance.yahoo.com - December 22 at 9:23 PM
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Genocea Bioscience, Inc. (GNCA) & Lead Plaintiff Deadline - January 2, 2018SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Genocea Bioscience, Inc. (GNCA) & Lead Plaintiff Deadline - January 2, 2018
finance.yahoo.com - December 20 at 5:18 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint on Behalf of Genocea Biosciences, Inc. Shareholders and Lead Plaintiff Deadline Set for January 2, 2018 – GNCASHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint on Behalf of Genocea Biosciences, Inc. Shareholders and Lead Plaintiff Deadline Set for January 2, 2018 – GNCA
finance.yahoo.com - December 20 at 5:18 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Genocea Biosciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2018 - GNCASHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Genocea Biosciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2018 - GNCA
finance.yahoo.com - December 18 at 5:20 PM
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Genocea Bioscience, Inc. (GNCA) & Lead Plaintiff Deadline: January 2, 2018SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Genocea Bioscience, Inc. (GNCA) & Lead Plaintiff Deadline: January 2, 2018
finance.yahoo.com - December 13 at 5:31 PM
Scott+Scott, Attorneys at Law, LLP Filed Class Action Against Genocea Biosciences, Inc. (GNCA) – Lead Plaintiff ... - Business Wire (press release)Scott+Scott, Attorneys at Law, LLP Filed Class Action Against Genocea Biosciences, Inc. (GNCA) – Lead Plaintiff ... - Business Wire (press release)
www.businesswire.com - December 13 at 9:47 AM
Scott+Scott, Attorneys at Law, LLP Filed Class Action Against Genocea Biosciences, Inc. (GNCA) – Lead Plaintiff Deadline is January 2ndScott+Scott, Attorneys at Law, LLP Filed Class Action Against Genocea Biosciences, Inc. (GNCA) – Lead Plaintiff Deadline is January 2nd
finance.yahoo.com - December 12 at 5:47 PM
GNCA LOSS NOTICE: Rosen Law Firm Reminds Genocea Biosciences, Inc. Investors of Important Deadline in Class Action – GNCAGNCA LOSS NOTICE: Rosen Law Firm Reminds Genocea Biosciences, Inc. Investors of Important Deadline in Class Action – GNCA
finance.yahoo.com - December 12 at 5:47 PM
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Genocea Biosciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2018 - GNCAINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Genocea Biosciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2018 - GNCA
finance.yahoo.com - December 12 at 9:55 AM
Reviewing Genocea Biosciences (GNCA) & Its RivalsReviewing Genocea Biosciences (GNCA) & Its Rivals
www.americanbankingnews.com - December 12 at 8:48 AM
DEADLINE ALERT: Brower Piven Reminds Investors of Upcoming Deadline in Class Action Lawsuit and Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Genocea Bioscience, Inc. to Contact the FirmDEADLINE ALERT: Brower Piven Reminds Investors of Upcoming Deadline in Class Action Lawsuit and Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Genocea Bioscience, Inc. to Contact the Firm
finance.yahoo.com - December 11 at 5:33 PM
Genocea Biosciences Inc (GNCA) Given Average Rating of "Buy" by BrokeragesGenocea Biosciences Inc (GNCA) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - December 8 at 8:06 AM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Genocea Bioscience, Inc. (GNCA) & Lead Plaintiff Deadline: January 2, 2018SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Genocea Bioscience, Inc. (GNCA) & Lead Plaintiff Deadline: January 2, 2018
finance.yahoo.com - December 6 at 5:22 PM
IMPORTANT GENOCEA BIOSCIENCES, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of investors who purchased and suffered losses in Genocea Biosciences, Inc.IMPORTANT GENOCEA BIOSCIENCES, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of investors who purchased and suffered losses in Genocea Biosciences, Inc.
finance.yahoo.com - December 5 at 5:17 PM
The Klein Law Firm Notifies Investors of a Class Action Filed on Behalf of Genocea Biosciences, Inc. Shareholders and a Lead Plaintiff Deadline of January 2, 2018The Klein Law Firm Notifies Investors of a Class Action Filed on Behalf of Genocea Biosciences, Inc. Shareholders and a Lead Plaintiff Deadline of January 2, 2018
finance.yahoo.com - December 4 at 5:20 PM
EQUITY ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Genocea Biosciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2018 - GNCAEQUITY ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Genocea Biosciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2018 - GNCA
finance.yahoo.com - December 1 at 4:50 PM
INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Genocea Bioscience, Inc. (NASDAQ: GNCA) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action LawsuitINVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Genocea Bioscience, Inc. (NASDAQ: GNCA) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
finance.yahoo.com - November 30 at 5:17 PM
GNCA EQUITY ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Genocea Biosciences, Inc. and a Lead Plaintiff Deadline of January 2, 2018GNCA EQUITY ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Genocea Biosciences, Inc. and a Lead Plaintiff Deadline of January 2, 2018
finance.yahoo.com - November 30 at 9:58 AM
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Genocea Bioscience, Inc. (GNCA) & Lead Plaintiff Deadline: January 2, 2018SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Genocea Bioscience, Inc. (GNCA) & Lead Plaintiff Deadline: January 2, 2018
finance.yahoo.com - November 29 at 5:40 PM
Glancy Prongay & Murray LLP Commences Investigation on Behalf of Genocea Biosciences, Inc. Investors (GNCA) - Business Wire (press release)Glancy Prongay & Murray LLP Commences Investigation on Behalf of Genocea Biosciences, Inc. Investors (GNCA) - Business Wire (press release)
www.businesswire.com - November 29 at 9:33 AM

SEC Filings

Genocea Biosciences (NASDAQ:GNCA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Genocea Biosciences (NASDAQ:GNCA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Genocea Biosciences (NASDAQ GNCA) Stock Chart for Monday, February, 19, 2018

Loading chart…

This page was last updated on 2/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.